Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results (Showing 1 to 19 of 19)As of 22-Nov-2009
New Screen 

All Reports | Brokerage Reports | Independent Reports
Release
Date [down]		 Contributor Author Title Pages Price StarMine Author Rating More Info
EPS Accuracy * Portfolio Return **
17-Nov-09Caris & CompanyDavid MoskowitzPRX-Ultram ER Launch Underway, Raising Estimates9$25  View Abstract
17-Nov-09Caris & CompanyDavid MoskowitzCRXL-Hot Property, Well Capitalized, Generating Cash8$25  View Abstract
13-Nov-09Caris & CompanyDavid MoskowitzENZN - Downgrade to 2*/Above Average and Price Target to $117$25  View Abstract
10-Nov-09Caris & CompanyDavid MoskowitzENZN - Divesting Specialty Pharma & Contract Mfr. Businesses8$25  View Abstract
9-Nov-09Caris & CompanyDavid MoskowitzPRX-Right Time, Right Place, Right Products – Maintain 1*/Buy, $25 Price Target9$25  View Abstract
6-Nov-09Caris & CompanyDavid MoskowitzEBS-3Q Light on Biothrax Order Timing9$25  View Abstract
4-Nov-09Caris & CompanyDavid MoskowitzENZN - Management Steadfast In Its Plans & Reducing Costs8$25  View Abstract
4-Nov-09Caris & CompanyDavid MoskowitzONXX - Maintain 2*Above Average Rating11$25  View Abstract
4-Nov-09Caris & CompanyDavid MoskowitzCRXL-3Q EPS In-line, Lower Revenues and Margins9$25  View Abstract
2-Nov-09Caris & CompanyDavid MoskowitzVNDA - 3Q Results Highlight Fanapt’s Success9$25  View Abstract
30-Oct-09Caris & CompanyDavid MoskowitzDEPO - 3Q As Expected9$25  View Abstract
30-Oct-09Caris & CompanyDavid MoskowitzIDIX - NVS Passes on IDX-18410$25  View Abstract
29-Oct-09Caris & CompanyDavid MoskowitzMYL - 3Q Upside Mostly Expected But Still Feels Good8$25  View Abstract
28-Oct-09Caris & CompanyDavid MoskowitzAUXL-Waiting for FDA Decision on Xiaflex8$25  View Abstract
22-Oct-09Caris & CompanyDavid MoskowitzLLY-Maintain 2*/Above Average, Reducing Target9$25  View Abstract
14-Oct-09Caris & CompanyDavid MoskowitzVNDA- Maintain 1*/Buy, Price Target Goes to $209$25  View Abstract
13-Oct-09Caris & CompanyDavid MoskowitzONXX-Long-Term Prospects Enhanced By Proteolix Deal9$25  View Abstract
12-Oct-09Caris & CompanyDavid MoskowitzCRXL-Raising Estimates on Benefits of J&J Premium8$25  View Abstract
5-Oct-09Caris & CompanyDavid MoskowitzENZN - Two Pieces of Good News8$25  View Abstract

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.